IQVIA Holdings Inc. $IQV Shares Sold by Edmond DE Rothschild Holding S.A.

Key Points

• Edmond DE Rothschild Holding S.A. has reduced its stake in IQVIA Holdings Inc. by 9.4%, now holding 67,585 shares valued at approximately $11.9 million.
• Several institutional investors, including Pacer Advisors Inc. and JPMorgan Chase & Co., significantly increased their positions in IQVIA during the first quarter, highlighting strong institutional interest.
• IQVIA reported $2.81 earnings per share, surpassing analysts' expectations, and has set a guidance for FY 2025 EPS between 11.750 and 12.050.

Edmond DE Rothschild Holding S.A. lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 9.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 67,585 shares of the medical research company's stock after selling 7,039 shares during the quarter. Edmond DE Rothschild Holding S.A.'s holdings in IQVIA were worth $11,915,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the stock. AQR Capital Management LLC boosted its holdings in shares of IQVIA by 58.1% in the 1st quarter. AQR Capital Management LLC now owns 675,597 shares of the medical research company's stock valued at $115,865,000 after purchasing an additional 248,353 shares during the last quarter. Advisors Asset Management Inc. boosted its holdings in shares of IQVIA by 25.3% in the 1st quarter. Advisors Asset Management Inc. now owns 5,826 shares of the medical research company's stock valued at $1,027,000 after purchasing an additional 1,176 shares during the last quarter. AlTi Global Inc. boosted its holdings in shares of IQVIA by 64.3% in the 1st quarter. AlTi Global Inc. now owns 2,935 shares of the medical research company's stock valued at $517,000 after purchasing an additional 1,149 shares during the last quarter. Aprio Wealth Management LLC boosted its holdings in shares of IQVIA by 48.5% in the 1st quarter. Aprio Wealth Management LLC now owns 1,864 shares of the medical research company's stock valued at $329,000 after purchasing an additional 609 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its holdings in shares of IQVIA by 85.8% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 72,201 shares of the medical research company's stock valued at $12,729,000 after purchasing an additional 33,341 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Stock Up 0.0%

Shares of IQV traded up $0.04 during midday trading on Monday, hitting $187.72. The company had a trading volume of 1,304,279 shares, compared to its average volume of 1,920,680. The company's 50 day moving average price is $179.88 and its 200 day moving average price is $167.23. The stock has a market cap of $31.91 billion, a price-to-earnings ratio of 27.17, a PEG ratio of 2.06 and a beta of 1.32. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $248.03. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.04. The company had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company's revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analyst Weigh In

IQV has been the topic of a number of research analyst reports. Evercore ISI lifted their price target on shares of IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a report on Wednesday, July 9th. Barclays upped their price target on shares of IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 23rd. JPMorgan Chase & Co. lowered their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a report on Monday, May 19th. Redburn Partners set a $214.00 price target on IQVIA in a report on Wednesday, September 3rd. Finally, William Blair reiterated an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, IQVIA presently has a consensus rating of "Moderate Buy" and a consensus price target of $229.86.

Insider Transactions at IQVIA

In related news, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. This represents a 15.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.